Making changes in the pharma industry in operations is a slightly more expensive process because of larger compliances and ...

The offering included about 8.5 million shares of Bayer, which is about 0.9% of the company. Initial reports stated that the ...

In today's Pharmaceutical Executive Daily, Bayer shares briefly dip after activist investor Inclusive Capital offloads its ...

Gilead will pay $1.675 billion upfront plus up to $500 million in milestones to obtain OM336, positioning BCMA-targeted ...

High-sensitivity sequencing of recurrent, cell-type–specific variants aims to strengthen causal inference versus germline ...

A Significant Shift in ASP Reporting. Beginning in 2026, CMS is requiring pharmaceutical manufacturers to submit “reasonable ...

In today's Pharmaceutical Executive Daily, Pfizer warns shareholders to reject an unsolicited mini-tender offer from Tutanota ...

Tutanota offered $32 per Pfizer share for up to 1 million shares, expiring April 13, 2026, with plans to extend the bid until ...

Acquired hypothalamic obesity is typically precipitated by hypothalamic insult from tumors, treatment, trauma, stroke, or ...

FDA has provided opportunities for R&D in rare disease, although recent developments have caused significant setbacks to occur. The rare disease space has always been uniquely difficult for drug ...

Icotyde is the first targeted oral peptide IL‑23 receptor antagonist, designed to interrupt a core psoriasis inflammatory axis while avoiding injection-based administration typical of IL‑23 biologics.

In a conversation with Pharmaceutical Executive DeYoung explains that an end-to-end patient support model is designed to ...